MONICA
CABRERO CALVO
Investigadora Predoctoral
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (9)
2022
-
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Cancers, Vol. 14, Núm. 22
-
CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441
2021
-
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928
-
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 10, pp. e801-e809
-
Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors
Bone Marrow Transplantation
2017
-
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59
2016
-
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815
-
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: A pilot trial from the GETH and GELLC (CLL4 trial)
Bone Marrow Transplantation